<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The purpose of this study was to evaluate the predictive ability of PTGIS for <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Protein expression of PTGIS was analyzed on tissue microarray consisting of 117 CRC cases with <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> (M1) and 104 cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> without <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> at least 5 years after resection of primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> (M0) by immunohistochemistry </plain></SENT>
<SENT sid="2" pm="."><plain>Expression of PTGIS in 147 of 221 of <z:e sem="disease" ids="C1402294" disease_type="Disease or Syndrome" abbrv="">primary lesions</z:e> exhibited positive staining </plain></SENT>
<SENT sid="3" pm="."><plain>Moreover, the PTGIS expression was significantly higher in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>-M1 than <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>-M0 group </plain></SENT>
<SENT sid="4" pm="."><plain>More importantly, the 87% (20/23) heterochronous metastatic cases showed positive staining for PTGIS </plain></SENT>
<SENT sid="5" pm="."><plain>Collecting the primary and liver <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic tumor</z:e> samples from the same <z:hpo ids='HP_0003003'>colon cancer</z:hpo> patients, we tested the expression of PTGIS and revealed that the expression level of PTGIS in the <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">hepatic metastases</z:e> was noticeably higher than in the matched primary <z:hpo ids='HP_0003003'>colon cancer</z:hpo> tissues from the same patient in 9 out of 16 cases examined </plain></SENT>
<SENT sid="6" pm="."><plain>Logistic regression analysis indicated that the expression of PTGIS and lymph node involvement were risk factors in <z:hpo ids='HP_0003003'>colon cancer</z:hpo> <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> independent of the other variables </plain></SENT>
<SENT sid="7" pm="."><plain>In leave-one-out validation model, the combination of PTGIS and lymph node involvement yielded the 89.7% satisfactory sensitivity and 83% specificity for detection of <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">hepatic metastasis</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Kaplan-Meier survival analysis revealed a correlation between higher PTGIS expression levels and shorter overall survival times </plain></SENT>
<SENT sid="9" pm="."><plain>In conclusion, our results suggest that PTGIS combined with lymph node involvement may be used as accurate predictors of <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>